Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radotinib in Ph+ CML Resistant/Intolerant to TKIs
NCT01602952Phase 2Completed
- Sponsor
- Il-Yang Pharmaceutical
- Start
- Jul 2008
- Primary completion
- Oct 2012
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 3
01
Overview
A Phase 2 trial of radotinib in chronic myeloid leukemia (CML), sponsored by Il-Yang Pharmaceutical. Started Jul 2008; status: completed.
02
Drugs
radotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01602952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01602952.